Phase 3 trials are still ongoing, and the medication will need regulatory approval from the MHRA (Medicines and Healthcare products Regulatory Agency) before it can be prescribed
In this Analysis, we searched for relevant literature on the effects of GLP-1RAs across a range of illnesses, gathering and describing the available pre-clinical and mechanistic (278 studies) and clinical (96 studies) evidence for cognitive disorders, substance-use disorders, psychotic disorders, mood and anxiety disorders, eating disorders, and others
However, discontinuation rates in Phase 2 were low (~6% at 12 mg), which suggests side effects were manageable for most participants
For the bigger picture, see how Do GLP Patches Work
Understanding the regulatory landscape surrounding retatrutide purchases is essential to ensure compliance with applicable laws
These strategic moves in the consumer health space have benefited the company from a financial perspective
